

## *In vivo* quercetol effect in lead acetate poisoning

Florentina RONCEA\*, Horatiu MIRESAN, Adrian Cosmin ROSCA, Mihaela BRATU and Antoanela POPESCU

*Ovidius University of Constanta, Faculty of Pharmacy, University Street No.1, Constanta, Romania*

**Abstract** The present study investigated the influence of quercetol upon  $\delta$ -aminolevulinic acid ( $\Delta$ -ALA) urine concentration as marker of lead poisoning. The study was conducted on six lots of 6 mature Wistar rats of both sexes, lots not poisoned treated with different concentrations of quercetol (Q1, Q2), control (L6M), lot poisoned untreated (L3Pb), lots poisoned and treated with Q (L4Q1Pb and L5Q2Pb). After 11 days urine from 24 hours was collected for  $\Delta$ -ALA spectrophotometric assay and testing the significance of mean difference of by "t" test Student at  $p < 0.05$ . Statistical analysis of the data presented shows that compared to L2Q2 and L6M the amount of  $\delta$ -ALA excreted in urine under quercetol influence (L4Q1Pb) shows statistical significance compared to (L2Q2) the amount of  $\delta$ -ALA excreted in urine compared to (L3Pb) shows statistical significance. Different concentrations of quercetol (Q1, Q2), did not produce significant changes in the  $\delta$ -ALA excreted compared with values of (L3Pb). Difference between means is probably due to sampling fluctuation, is not significant, reduced growth to eliminate  $\delta$ -ALA on L4Q1Pb and L5Q2Pb is believed to be due to iron complex formation, reducing hemoglobin synthesis. From the results we conclude that hem biosynthesis does not start to grow under quercetol protection. The obtained data are not relevant statistical since interpretations were performed on non homogeneous groups in number of individuals, the percentage of mortality variability and high levels of standard deviation calculated from each lot.

**Keywords:** lead acetate poisoning, quercetol,  $\delta$ -aminolevulinic acid urine assay, possible antidote.

### 1. Introduction

As unprofessional poisoning with inorganic lead compounds produce haematotoxicity (enzyme inhibition with blocking chain thiolofore porphyrin and hem biosynthesis interference, increased  $\delta$ -aminolevulinic acid in serum, urine elimination increased, decreased hemoglobin and number of erythrocytes, erythrocyte membrane alteration) and nephrotoxicity (shown to tubules convoluted proximal and distal) and antidotes used show non-specificity and toxicity (nephrotoxicity, depletion  $\text{Ca}^{2+}$ ,  $\text{Zn}^{2+}$  ions effects on skin) [1 - 7] we chosed chelating - natural ligands (quercetol, rutoside) that have fewer toxic effects and act as an possible antidote.

One mechanism involved in lead poisoning is aerobic oxidation of  $\delta$ -aminolevulinic acid, metal

catalyzed reaction at physiological pH, with appearance of several species of free radicals, which cause oxidative stress at the level of the accumulated  $\delta$ -aminolevulinic acid (kidney) or autooxidation and enolisation [8 - 10].

The consequence consists in increased activity of stress enzymes, superoxide dismutase and catalase, due to alteration of cell membrane and hemolysis caused by lead [12, 13].

Quercetol (3, 3', 4', 5', 7-pentahydroxiflavone) selection as a vegetal principle with possible antidote properties is based on multiple experimental observations: it forms stable complexes with plurivalent metal ions ( $\text{Cu}^{2+}$ ,  $\text{Fe}^{2+}$ ,  $\text{Fe}^{3+}$ ,  $\text{Zn}^{2+}$ ,  $\text{Al}^{3+}$ ) [1], *in vitro* verification of these complexes formation and stability [2 - 4], *in vivo* decrease of oxidative stress (superoxiddismutase, catalase) in crustaceans (*Euxinia maeotica*) and molluscs (*Mytillus galloprovincialis*) poisoned with lead

acetate [5, 7], annihilation of some toxic lead acetate poisoning effects [8, 9], free radicals captation (inhibition of membrane lipids peroxidation, protection against oxidative stress – antioxidant activity), and even neuroprotective effect [10, 11], when the plasmatic concentration of homovanilic acid increases [10 - 12].

Previously conducted researches on mice poisoned with lead acetate and treated with quercetol revealed quercetol role in lowering enzymatic activity of superoxide dismutase (SOD), catalase, demonstrating indirect action as possible antidote (ratio of lead acetate bioinactivation / quercetol = 2.18) [14].

These results have motivated the resumption experiments on laboratory animals to determine other parameters that may be markers of reducing toxic effect [7].

The aim of the present study is to *in vivo* investigate the influence of quercetol upon urine  $\delta$ -aminolevulinic acid ( $\Delta$ -ALA) concentration as lead poisoning marker.

## 2. Experimental

The study was conducted on six lots each of 6 mature rats of both sexes, Wistar, weighing specified ( $150 \pm 5$  g), provided by Cantacuzino Institute, Bucharest, maintained under laboratory bioclimatic conditions and received deionized drinking water *ad libidum* administered. The animals were treated daily at the same time (9 a.m.), by gavage, with doses of quercetol, lead acetate or deionized water (if applicable) for a period of 12 days.

The researches were conducted at Ovidius University of Constanta. All procedures were performed in accordance with the ECC Directive 86/609/EEC of 24 November 1986 and Ordinance 37 of the Romanian Government from 2 February 2002, regarding research bioethics.

Lots have received the following treatment:

lot 1 - quercetol 0.05 g/kg/body weight;

lot 2 - quercetol 0.1 g / kg / body weight;

lot 3 - 20% lead acetate solution, 0.1 mL / kg / body weight;

lot 4 - 20% lead acetate solution, 0.1 mL / kg / body weight; and quercetol 0.05 g / kg / body weight;

lot 5 - 20% lead acetate solution, 0.1 mL / kg / body weight; and quercetol 0.1 g / kg / body weight;

lot 6 - control, deionized water, 0.1 mL / kg.

Quercetol was administered p.o. by suspending 0.5 g and 1 g of sodium carboxymethylcellulose 1% mucilage completed to 5 mL with deionized water and lead acetate was administered as a 20% solution, 0.1 mL / kg.

Quercetol  $\times 2$  H<sub>2</sub>O, lead acetate and sodium carboxymethylcellulose come from companies Merck and Roth.

After 11 days of dosing was collected urine from 24 hours to determine the  $\Delta$ -aminolevulinic acid concentration.

### Urine $\delta$ -ALA ( $\delta$ -aminolevulinic acid) assay

$\Delta$ -ALA is the first intermediate substrate in the synthesis of heme and is neurotoxic, at least in animals [5 - 7, 12 - 14]. Quantification of  $\Delta$ -ALA can also be achieved by colorimetric methods based on  $\delta$ -aminolevulinic acid condensation with acetylacetone at pH = 4.6, resulting a pyrrole structure which reacts with p -dimethylbenzaldehyde (PABA) in ethhyl acetate medium to form a red compound [15].

Urine  $\delta$ -aminolevulinic acid concentration is calculated using the formula:

$$\text{mg } \delta\text{-ALA / L urine} = \frac{AP - APB}{AS} \times 50 \quad (1)$$

where:

AP – sample absorbance,

APB – blank absorbance,

AS – standard absorbance

Colorimetric measurements have been done using a Jasco V-630 spectrophotometer.

Urine normal values for  $\delta$ -aminolevulinic acid are considered to be in the 0.1 - 5.7 mg/L range.

In lead poisoning, excretion of  $\delta$ -ALA in the urine increases, and may reach 40 mg / L [13].

In order to evaluate the results of statistical calculations, it is necessary to decide whether the differences obtained between analyzed samples are random or real by testing the significance of mean difference  $\delta$ -aminolevulinic acid concentration by "t" test Student at  $p < 0.05$  [11].

To this aim we made the following notations:

L2Q2 - quercetol 0.1 g / kg / body weight;

L3Pb - 20% lead acetate solution, 0.1 mL / kg / body weight;

L4Q1Pb - 20% lead acetate solution, 0.1 mL / kg / body weight; and quercetol 0.05 g / kg / body weight;

L5Q2Pb - 20% lead acetate solution, 0.1 mL / kg / body weight; and quercetol 0.1 g / kg / body ;

L6M - control, deionized water, 0.1 mL / kg.

We analyzed the significance of mean difference  $\delta$ -aminolevulinic acid concentration as follows: L2Q2-L3Pb, L2Q2-L4Q1Pb, L2Q2-L5Q2Pb, L2Q2-L6M, L3Pb-L2Q2, L3Pb-L4Q1Pb, L3Pb-L5Q2Pb, L3Pb-L6M, L4Q1Pb-L5Q2Pb, L4Q1Pb-L6M, L5Q2Pb-L6M.

### 3. Results and Discussions

Urine  $\delta$ -aminolevulinic acid concentration variation is given per lot in cumulative table, **Table 1**.

Results are expressed as mean values  $\pm$  standard deviation.

**Table 1.** Urine  $\delta$ -aminolevulinic acid concentration variation (lots 2-6)

Lot	$\delta$ -aminolevulinic acid mg/L ( $\bar{x} \pm S.D.$ )
2	4.39 $\pm$ 2.61
3	46.63 $\pm$ 9.89
4	33.18 $\pm$ 7.54
5	36.48 $\pm$ 11.88
6	2.72 $\pm$ 0.14

**Tables 2 - 6** present results of significance analysis mean difference  $\delta$ -aminolevulinic acid concentration determined in urine at the end of the experiment. Significant values of parameter significance analysis are noted where appropriate in bold italics.

**Table 2.** Influence of quercetol treatment on  $\delta$ -aminolevulinic acid concentration in lead acetate poisoning. Significance of mean difference by "t" test student at  $p < 0.05$  for L2Q2

Variables	Mean (conc. mg/L)	Standard dev.	Nr. cases	Mean dif.	Standard dev. of dif.	t	Liberty grades	p
L2Q2	4.396	3.693						
L3Pb	52.146	16.074	3	- 47.75	13.724	-6.02	2	<b>0.026</b>
L2Q2	4.396	3.693						
L4Q1Pb	37.386	12.232	3	- 32.99	9.415	-6.06	2	<b>0.026</b>
L2Q2	4.396	3.693						
L5Q2Pb	36.516	16.845	3	- 32.12	16.572	-3.35	2	0.078
L2Q2	4.396	3.693						
L6M	2.626	0.402	3	1.77	3.988	0.768	2	0.5224

**Table 3.** Influence of quercetol treatment on  $\delta$ -aminolevulinic acid concentration in lead acetate poisoning. Significance of mean difference by "t" test student at  $p < 0.05$  for L3Pb

Variables	Mean (conc. mg/L)	Standard dev.	Nr. cases	Mean dif.	Standard dev. of dif.	t	Liberty grades	p
L3Pb	52.146	16.074						
L2Q2	4.396	3.69	3	47.75	13.7245	6.026	2	<b>0.0264</b>
L3Pb	46.632	17.142						
L4Q1Pb	33.182	13.056	4	13.45	15.206	1.769	3	0.175
L3Pb	52.146	16.074						
L5Q2Pb	36.516	16.845	3	15.63	29.158	0.928	2	0.451
L3Pb	46.63	17.142						
L6M	2.69	0.357	4	43.935	17.236	5.098	3	<b>0.0145</b>

**Table 4.** Influence of quercetol treatment on  $\delta$ -aminolevulinic acid concentration in lead acetate poisoning. Significance of mean difference by "t" test student at  $p < 0.05$  for L4Q1Pb

Variables	Mean (conc. mg/L)	Standard dev.	Nr. cases	Mean dif.	Standard dev. of dif.	t	Liberty grades	p
L4Q1Pb	37.386	12.232						
L2Q2	4.396	3.693	3	32.99	9.415	6.068	2	<b>0.026</b>
L4Q1Pb	33.182	13.056						
L3Pb	46.632	17.142	4	-14.45	15.206	-1.769	3	0.175
L4Q1Pb	33.182	13.056						
L5Q2Pb	36.516	16.845	3	0.87	11.945	0.126	2	0.911
L4Q1Pb	33.182	13.056						
L6M	2.697	0.357	4	30.485	13.394	4.551	3	<b>0.019</b>

**Table 5.** Influence of quercetol treatment on  $\delta$ -aminolevulinic acid concentration in lead acetate poisoning. Significance of mean difference by "t" test student at  $p < 0.05$  for L5Q2Pb

Variables	Mean (conc. mg/L)	Standard dev.	Nr. cases	Mean dif.	Standard dev. of dif.	t	Liberty grades	p
L5Q2Pb	36.516	16.845						
L2Q2	4.396	3.693	3	32.12	16.572	3.356	2	0.078
L5Q2Pb	36.516	16.845						
L3Pb	52.146	16.074	3	-15.63	29.158	-0.928	2	0.451
L5Q2Pb	36.516	16.845						
L4Q1Pb	37.386	12.232	3	-0.87	11.945	-0.126	2	0.9111
L5Q2Pb	36.516	16.845						
L6M	2.626	0.402	3	33.89	17.179	3.416	2	0.076

**Table 6.** Influence of quercetol treatment on  $\delta$ -aminolevulinic acid concentration in lead acetate poisoning. Significance of mean difference by "t" test student at  $p < 0.05$  for L6M

Variables	Mean (conc. mg/L)	Standard dev.	Nr. cases	Mean dif.	Standard dev. of dif.	t	Liberty grades	p
L6M	2.626	0.402						
L2Q2	4.396	3.693	3	-1.77	3.988	-0.768	2	0.522
L6M	2.6975	0.357						
L3Pb	46.632	17.142	4	-43.935	17.236	-5.098	3	<b>0.0145</b>
L6M	2.6975	0.357						
L4Q1Pb	33.182	13.056	4	-30.845	13.394	-4.551	3	<b>0.0198</b>
L6M	2.626	0.402						
L5Q2Pb	36.516	16.845	3	-33.89	17.179	-3.416	2	0.0760

**Table 7.** Influence of quercetol treatment on  $\delta$ -aminolevulinic acid concentration in lead acetate poisoning. Significance of mean difference by "t" test student at  $p < 0.05$  for L4, L3 – L5

Variables	Mean (conc. mg/L)	Standard dev.	Nr. cases	Mean dif.	Standard dev. of dif.	t	Liberty grades	p
L4Q1Pb	33.182	13.056	4	-13.45	15.206	-1.769	3	0.175
L3Pb	46.632	17.142	4					
L5Q2Pb	36.516	16.845	3	-15.63	29.158	-0.928	2	0.451
L3Pb	52.146	16.074	3					

**Table 7** shows results of significance analysis mean difference of  $\delta$ -aminolevulinic acid concentration determined in urine at the end of experiment compared to lots L4Q1Pb and L5Q2Pb L3Pb.

Statistical analysis of the data presented shows that:

- compared to control group not poisoned (L2Q2 and L6M) the amount of  $\delta$ -ALA excreted in urine under quercetol influence (L4Q1Pb) shows statistical significance;
- compared to control group not poisoned (L2Q2) the amount of  $\delta$ -ALA excreted in urine compared to intoxicated group (L3Pb) shows statistical significance;
- none of any quercetol doses administered (0.05 g / kg b. w. and 0.1 g / kg b. w.) did not produce significant changes in the parameters analyzed ( $\delta$ -aminolevulinic acid concentration)

compared with values of intoxicated and untreated control group (L3Pb);

- difference between means is probably due to sampling fluctuation is not significant and can not be considered to affirm pharmacodynamic effect or value;
- reduced growth to eliminate  $\delta$ -ALA on poisoned and treated groups with quercetol is believed to be due to iron complex forming, reducing hemoglobin synthesis.

#### 4. Conclusions

From the results we conclude that hem biosynthesis does not start to grow under quercetol protection.

The obtained data are not relevant statistical since interpretations were performed on non homogeneous groups in number of individuals, the percentage of mortality variability and high levels of standard deviation calculated from each lot.

## 5. References

\*E-mail address: [florentinaroncea03@yahoo.com](mailto:florentinaroncea03@yahoo.com)

- [1]. F. Roncea, V. Istudor, M. M. Bratu and T. Negreanu Pîrjol, *Farmacia* **40** (2), 55 – 60 (2003) (in Romanian).
- [2]. F. Roncea, V. Istudor, M. M. Bratu, and T. Negreanu Pîrjol, *Magazine of Medicine and Pharmacy* **50**, Suppliment II, Târgu – Mureş, 271 – 274 (2004), (in Romanian).
- [3]. C. A., Costa., G. C. Trivelato, A. M. P. Pinto and E. J. H. Bechara, *Clin. Chem.* **43** (7), 1196 – 1202 (1997).
- [4]. N. Ercal., H. Gurer–Orhan and N. Aykin–Burns, *Curr. Top Med. Chem.*, **1** (6), 124 – 128, (2001).
- [5]. S. Kasperczyk, E. Birkner, A. Kasperczyk and J. Fiolka – Zalejska, *Ann. Agric. Environ. Med.*, **11**, 291 – 296 (2004).
- [6]. F. Roncea, Doctoral thesis, The University of Medicine and Pharmacy „Carol Davila”, Bucharest (2007), (in Romanian, abstract in English).
- [7]. Goodman Gilman’s and Joel. G. - *The Pharmacological basis of therapeutics*, Raven Press, N.Y. 1996, pp. 1645 - 1666.
- [8]. V. A. Voicu – *Clinical Toxicology*, Albatros Press, Bucharest, 1997, p. 121 – 126 (in Romanian).
- [9]. B. Kędzia, E. HoldErna-Kędzia, *Herba Polonica*, **55** (1), 99 – 108 (2009).
- [10]. M. Enoiu, *Farmacia* **49** (3), 7 – 25 (2001) (in Romanian).
- [11]. C. M. Smith, X. Wang., H. Hu and K. Kelsey, *Environ. Health Perspect.* **103**, 248 – 253 (1995).
- [12]. \*\*\* Romanian Pharmacopoeia, X<sup>th</sup> ed., Medical Press, Bucharest, 2009, p. 1125 – 1154 (in Romanian).
- [13]. M. Cotrău and M. Proca – *Clinical toxicology*, Medical Press, Bucharest, 1988, p. 103 – 116 (in Romanian).
- [14]. G. Țarălungă, F. Roncea, V. Istudor, *Farmacia*, **58** (1), 54 – 61 (2010).
- [15]. N. Roşoiu, M. Şerban, Gh. Badiu – *Laboratory methods and techniques used in biochemistry, vol. II, Clinclal biochemistry*, Muntenia&Leda Press, Constantza, 2000, p. 330 – 333 (in Romanian).

Submitted: May 21<sup>th</sup> 2013

Accepted in revised form: August 7<sup>th</sup> 2013